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INTRODUCTION
Greater than 10% of the total number of battlefield injuries occur to the eyes, resulting in significant morbidity. 1 The potential for ocular infection by penetrating injuries is significant, due to the nature of the organisms encountered in battlefield environments, and the delay between the time of injury and adequate therapeutic intervention. This proposal was designed to analyze the effectiveness of antibiotics, anti-inflammatory drugs, and non-conventional agents that target bacterial and host virulence factors, with the goal of improving the outcome of infections that typically result in significant vision loss. The goal is to sterilize the eye, arrest inflammation, and preserve vision following post-traumatic endophthalmitis.
BODY OF RESEARCH
Statement of Work (Abbreviated). Project tasks (experiments) included 7 experiments encompassing the Aims listed below. All experiments were performed using an experimental rabbit model of Bacillus cereus endophthalmitis. In the model, 100 bacilli/0.1 ml are injected into the mid-vitreous of one eye, while the contralateral eye is injected with 0.1 ml PBS (surgical control) or is left undisturbed (absolute control). At designated time points during infection, treatment was administered (intravitreal drug and/or surgery, with proper controls). At designated time points, eyes were electroretinographed (measurement of retinal function) and removed after euthanasia for analysis of myeloperoxidase activity (from inflammatory cells), drug concentrations, bacterial growth, and histology. Specific experiments included: 1) analysis of the efficacy of antibiotics or antibiotic combinations against experimental Bacillus endophthalmitis, 2) analysis of the efficacy of antibiotics against B. cereus spores in the eye before and after germination, 3) analysis of the efficacy of vitrectomy in conjunction with the most effective antibiotic for treatment of B. cereus endophthalmitis, 4) analysis of the efficacy of an anti-inflammatory agent, prednisolone acetate, in conjunction with the most effective antibiotic for B. cereus endophthalmitis, 5) analysis of the efficacy of anti-TNFα in conjunction with the most effective antibiotic for B. cereus endophthalmitis, 6) analysis of the efficacy of polyclonal antibody generated against B. cereus toxins (anti-toxin) in conjunction with the most effective antibiotic for B. cereus endophthalmitis, and 7) analysis of the efficacy of polyclonal antibody generated against B. cereus flagella (anti-flagella) in conjunction with the most effective antibiotic for B. cereus endophthalmitis.
Aim 1: Conventional Therapeutics. We hypothesized that proper antibiotic/anti-inflammatory and surgical intervention is critical for preserving vision during Bacillus endophthalmitis.

Aim 1.1 Antibiotics: Intravitreal administration of antibiotics against vegetative and spore forms of B. cereus during the early logarithmic bacterial growth stage of endophthalmitis.
Summary: In Wiskur et al. 2 , we published that intravitreal administration of antibiotics at 2 h or 4 h postinfection successfully preserved vision following experimental B. cereus endophthalmitis. These studies were expanded to analyze the fate of the eye after our latest analysis point of 8 h postinfection.
Experimental Design Summary: Eyes were intravitreally infected with 100 CFU B. cereus. 0.1 mL of gatifloxacin (0.3%), vancomycin (1.0%), or a combination of both antibiotics at these concentrations were intravitreally injected at either 2, 4, or 6 h postinfection. Eyes were analyzed at 12, 24, and 36 or 48 h postinfection by bacterial quantitation, electroretinography, inflammatory cell quantitation, and histology (N≥5 eyes per group).
Progress To Date: All antibiotic treatments sterilized all eyes, except vancomycin administered at 6 h, as previously described. 2 Retinal function analysis is summarized in Figure 1 . The results demonstrate the importance of early intravitreal injection of either gatifloxacin or vancomycin (not both, as the retinal function retained was less and inflammation was greater with the combination than either antibiotic alone). In terms of better retinal function outcome, 2 h treatment > 4 h treatment > 6 h treatment, and vancomycin = gatifloxacin > vancomycin + gatifloxacin. Inflammatory cell influx into infected eyes is presented in Figure 2 . In terms of least inflammation after treatment, 2 h treatment > 4 h treatment > 6 h treatment, and vancomycin > gatifloxacin > vancomycin + gatifloxacin. In approximately 45% of cases of severe B. cereus endophthalmitis, the eye must be removed. 3, 4 Ocular architecture remained intact following 6 h treatment with either antibiotic (Figure 3 ), indicating that treatment delays of 6 h may not salvage useful vision, but globe architecture may be retained.
Data Not Shown: Bacterial counts (results discussed in Progress to Date) and histology sections and photographs of eyes from each treatment group at all endpoints. Relevance: These results reiterate that early intravitreal treatment of posterior segment bacterial infections is critical for salvaging not only vision, but also the architecture of the globe itself. In the battlefield where treatment delays are expected, intravitreal administration of antibiotics following post-traumatic ocular injury may pre-empt infection and improve visual outcome.
Aim 1.2 Antibiotics Plus Anti-Inflammatory Agents: Intravitreal administration of antibiotics plus antiinflammatory agents against B. cereus during the early logarithmic bacterial growth stage of endophthalmitis.
Summary: In Wiskur et al. 2 , we reported that intravitreal administration of dexamethasone (1.0%) with gatifloxacin (0.3%) or vancomycin (1.0%) did not limit inflammation or improve the outcome of infection compared with treatments with antibiotics alone. The present studies analyzed the effectiveness of prednisolone acetate in improving the outcome of experimental B. cereus endophthalmitis.
Experimental Design Summary: Eyes were intravitreally infected with 100 CFU B. cereus. 0.1 mL of vancomycin (1.0%) or a combination of vancomycin and prednisolone acetate (1.0%) were intravitreally injected at either 2, 4, or 6 h postinfection. Eyes were analyzed at 12, 24, and 36 or 48 h postinfection by bacterial quantitation, electroretinography, inflammatory cell quantitation, and histology (N≥5 eyes per group).
Progress To Date:
Vancomycin treatments sterilized all eyes, except vancomycin administered at 6 h, as previously described. 2 Retinal function analysis is summarized in Figure 4 . In general, administration of vancomycin + prednisolone was not effective in reducing retinal function loss compared to the use of vancomycin alone. However, treatment with vancomycin + prednisolone did reduce inflammatory cell influx compared to that of vancomycin alone ( Figure 5 ). For 2 h treatment, differences in inflammation between treatment groups were noted at 24 and 48 h, while treatment at 4 h or 6 h resulted in differences at the latest time point only. The only potential difference observed between the treatment groups was in anterior segment inflammation observed via histology ( Figure 6 ). This observation correlates with less inflammatory cell counts in eyes treated with vancomycin + prednisolone ( Figure 5 ). There were no observable differences between treatment groups upon gross clinical examination ( Figure 6 ). Data Not Shown: Bacterial counts (discussed in Progress to Date) and histology sections and photographs of eyes from each treatment group at all endpoints.
Experiments Remaining: 1) A control group of treatment of infection with prednisolone alone is needed to complete the study. 2) Analysis of antibiotic concentrations in eyes from the experiments described above. 3) Comparison of treatment with gatifloxacin alone or gatifloxacin + prednisolone in experiments similar to those described in Aim 1.2.
Relevance: Although the administration of prednisolone acetate with vancomycin improved inflammation during infection, loss of retinal function was similar to that of eyes treated with vancomycin alone during infection. These results suggest that, like our recent findings 2 of lack of benefit of antibiotics in conjunction with dexamethasone, prednisolone acetate does not improve the therapeutic outcome of B. cereus endophthalmitis when combined with vancomycin. Further studies are needed to determine whether the combination of gatifloxacin and prednisolone improves therapeutic outcome.
Aim 1.3 Antibiotics Plus Surgery: The effect of vitrectomy plus intravitreal antibiotics against B. cereus during the late logarithmic bacterial growth stage of endophthalmitis.
Summary: As noted in the experiments above, treatment at 6 h postinfection resulted in loss of retinal function, but ocular architecture remained intact. Histology and photographs depicted the severe degree of inflammation in these eyes ( Figure  6 ). In clinical cases of this severity, vitrectomy is used to remove posterior segment debris in order to potentially salvage vision. This Aim was proposed to analyze the effectiveness of vitrectomy used in conjunction with antibiotics for treatment of late-stage B. cereus endophthalmitis.
Progress To Date:
These studies have not yet begun.
Aim 2: Non-Conventional Therapeutics. We hypothesized that blocking toxin activity, bacterial migration within the eye, and/or influx of inflammatory cells during B. cereus endophthalmitis will attenuate intraocular virulence and improve the therapeutic outcome of disease.
Aim 2.1 Blocking Toxin Activity: Intravitreal administration of anti-toxin raised to B. cereus toxins plus antibiotics against B. cereus during the early logarithmic bacterial growth stage of endophthalmitis.
Summary: We reported that toxin production in the eye during B. cereus endophthalmitis was responsible for the majority of retinal function loss during progressive infection. 5, 6 Others have reported that antisera raised to another ocular pathogen, Staphylococcus aureus, was effective in abrogating the effects of toxins during experimental endophthalmitis caused by that organism. 7, 8 We proposed a similar approach for treating B. cereus -combining anti-B. cereus toxin antisera with antibiotics during treatment at the early stages of infection when toxins are produced. The key is to kill the organism and arrest toxin activity.
Progress to date:
We are presently raising polyclonal antibody to B. cereus toxins for administration with antibiotics during experimental B. cereus endophthalmitis. In vivo testing has not yet begun.
Aim 2.2 Blocking Bacterial Migration: Intravitreal administration of anti-flagellar antibody raised to B. cereus flagella plus antibiotics against B. cereus during the early logarithmic bacterial growth stage of endophthalmitis.
Summary: We reported that B. cereus migration throughout the eye was important to the virulence of the organism. 6, 9 In an approach similar to that in Aim 2.1, we proposed to combine anti-B. cereus flagella antisera with antibiotics during treatment at the early stages of infection when bacteria are moving within the posterior segment of the eye. The key is to prevent migration of the organism into niches where they may circumvent antibiotic action while also killing the organisms.
Progress To Date:
We are presently purifying B. cereus flagella for use in generating polyclonal antibody for administration with antibiotics during experimental B. cereus endophthalmitis. In vivo testing has not yet begun.
Aim 2.3 Blocking Intraocular Influx of Inflammatory Cells: Intravitreal administration of anti-TNFα plus antibiotics against B. cereus during the early logarithmic bacterial growth stage of endophthalmitis.
Summary: We reported that TNFα is one of the pro-inflammatory cytokines synthesized in the eye during B. cereus endophthalmitis. 10 Using transgenic mice deficient in TNFα, we identified this cytokine as being important in recruitment of inflammatory cells into the eye during B. cereus endophthalmitis. 11 Pilot experiments in mice demonstrated that anti-TNFα reduced the inflammatory cell load when administered intravitreally alone at the time of infection, but the reduction was only 40% at 10 h postinfection. We proposed to analyze whether anti-TNFα combined with antibiotics effectively reduced inflammation and sterilized the eye during the early stages of B. cereus endophthalmitis. Relevance: We found that intravitreal administration of anti-TNFα (Remicade) to mouse eyes did not significantly reduce inflammation or alter function loss during B. cereus endophthalmitis. To date, no studies have analyzed the value of cytokine blockade in the treatment of intraocular infection, but studies do describe the use of anti-TNFα drugs in treating intraocular inflammation during uveitis. [12] [13] [14] Our preliminary results demonstrate that anti-TNFα blocking, even in the early stages of infection, may not improve the outcome of inflammation or infection. This is not surprising considering our findings of the production of additional chemotactic cytokines in the eye during experimental endophthalmitis in the mouse. 11 However, it is of interest to determine whether inflammation is kept at bay by anti-TNFα at a time past the 12 h time point.
KEY RESEARCH ACCOMPLISHMENTS
• We demonstrated that early and aggressive (i.e. intravitreal) antibiotic treatment of intraocular infection is critical in salvaging vision. • Delayed treatment (i.e. at 6 h postinfection) does not prevent significant vision loss but does arrest deterioriation of the globe itself. • Addition of prednisolone acetate to vancomycin in the treatment of B. cereus endophthalmitis does not improve retinal function loss but slightly dampens inflammation during infection. • Adjunct use of anti-TNFα may not alter the outcome of infection, but further studies are needed to determine whether inflammation is altered during infection.
REPORTABLE OUTCOMES
There are no reportable outcomes to date. We plan to submit the results of Aims 
CONCLUSIONS
Early and aggressive (i.e. intravitreal) administration of antibiotics are key to preventing significant vision loss and loss of the eye itself following penetrating injury and potential intraocular infection. The importance of these studies lies in identifying the timing in which an eye can be salvaged, even though sight may be lost. On the battlefield, as well as during accidental trauma, the timing from injury to treatment is critical, as is the type of treatment administered. Numerous studies have demonstrated that for posterior segment infections, systemic and/or topical antibiotic treatment is relatively useless (reviewed in reference 15). We demonstrated that intravitreal administration of antibiotics (with or without antiinflammatory drugs) salvages vision if given early and can rescue the eye if treatment is delayed. Although our work analyzes treatment of B. cereus endophthalmitis -the most devastating form of bacterial endophthalmitis -the results of these studies can be extrapolated toward treatment of infections with other vicious pathogens such as Staphylococcus aureus or Streptococcus pneumoniae, where courses of infection are slower but infection outcomes are just as devastating. The use of anti-inflammatory agents to alter inflammation remains controversial, and our results of prednisolone acetate/vancomycin or anti-TNFα/vancomycin administration do not help to clarify the issue. Future work should involve analyzing use of prednisolone acetate/gatifloxacin to identify any therapeutic improvements with this combination.
